Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 830 results for "novartis ag"

Novartis AG (NVS) Showing Support Near $100.70

The patented option-trade picking algorithms that power MarketIntelligenceCenter.com's Artificial Intelligence Center have selected a covered-call trade on Novartis AG (http://www.marketintelligencecenter.com/symbol/NVS"NVS) that includes 4.72% ... Individual.com, 1 week ago

Potential Novartis AG (NVS) Trade Targets 3.21% Return

After closing Tuesday at $101.89, Novartis AG (http://www.marketintelligencecenter.com/symbol/NVS"NVS) presents an attractive opportunity to get a 3.21% return in just 114 days, which is an annualized return of 10.28% (for comparison purposes only).
 Individual.com1 week ago Potential Novartis AG (NVS) Trade Has 4.51% Downside Protection  Individual.com1 week ago
Jutia Group

Amgen to appeal rejection of bid to block Novartis biosimilar drug

(Reuters) - Amgen Inc will appeal the rejection of its bid to block the sale of Novartis AG's biosimilar form of Neupogen, Amgen's blockbuster drug used to prevent infections in cancer patients, according to a court filing on Wednesday. The drug, ...
 Reuters6 days ago Company Update (NASDAQ:AMGN): Amgen to appeal rejection of bid to block Novartis biosimilar drug  Wall Street Select6 days ago Eleventh-Hour Call Buyers Target Amgen Inc. (AMGN)  Schaeffers Research1 week ago
[x]  
Bloomberg

From Snitch Pill to Xbox Sensors, Novartis Goes Digital

(Bloomberg) -- A decade ago, Joe Jimenez was peddling ketchup and baked beans. Now he's using Microsoft Corp.'s gaming technology and embedding Google Inc. sensors in contact lenses to reinvent the world's biggest drugmaker. As Novartis AG's ...
 Bloomberg1 week ago Novartis AG CEO, a San Francisco Native, Takes an Axe to Predecessor's Empire  BioSpace1 week ago

From Pills That Snitch to Xbox Sensors, Novartis Goes High-Tech

(Updates with share price in 16th paragraph.) As Novartis AG's chief executive, Jimenez is barreling down untested paths at the frontier of biology and digital technology to prepare for a future in which the use of smartphones and other digital ...
 Washington Post1 week ago

BRIEF-Cytos Biotechnology: Novartis buys out CAD 106 license agreement for CHF 4 mln

March 25 (Reuters) - Cytos Biotechnology AG : * Novartis buys out CAD 106 license agreement for 4 million Swiss francs ($4 million) * Is planning to use payment from Novartis to settle remaining payment obligations under outstanding convertible ...
 Reuters UK1 week ago EQS-Adhoc: Cytos Biotechnology AG: Novartis buys out CAD 106 license agreement for CHF 4 million  TeleTrader.com1 week ago DGAP-Adhoc: Cytos Biotechnology AG: Novartis buys out CAD 106 license agreement for CHF 4 million (english)  Swissquote1 week ago
Reuters

Novartis Wins Judge's Approval to Sell First-of-Kind Copycat

(Bloomberg) -- Novartis AG can sell in the U.S. the first imitation of a bioengineered drug approved by the Food and Drug Administration, a judge ruled in a setback for Amgen Inc. A federal judge in San Francisco allowed Novartis's Sandoz unit to ...
 Bloomberg1 week ago U.S. judge rejects Amgen injunction bid against Novartis Sandoz unit  Reuters1 week ago Amgen Devastated as Novartis AG Wins Approval to Sell First-of-a-Kind Copycat Drug  BioSpace1 week ago Novartis/Sandoz Clear to Market Their Biosimilar Zarxio  American Journal of Managed Care1 week ago
[x]  

QLT PhotoTherapeutics and Novartis Pharma AG's Visudyne (Macular Edema and Macular Degeneration) - Forecast and Market Analysis to 2023

Research and Markets (http://www.researchandmarkets.com/research/d88tp3/visudyne_macular) has announced the addition of the "Visudyne (Macular Edema and Macular Degeneration) - Forecast and Market Analysis to 2023" report to their offering. Macular ...
 Individual.com1 week ago Research and Markets: QLT PhotoTherapeutics and Novartis Pharma AG's Visudyne (Macular Edema and Macular Degeneration) - Forecast and Market Analysis to 2023  TMC Net1 week ago Cough Therapeutics Pipeline Review 2015 Featuring 34 Companies  Individual.com6 days ago Visudyne (Macular Edema and Macular Degeneration) - Market Analysis, Trends, Growth and Forecast to 2023  Digital Journal1 week ago
[x]  

Swiss stocks - Factors to watch on March 20

ZURICH, March 20 (Zurich) - The following are some of the main factors expected to affect Swiss stocks on Friday: NOVARTIS A U.S. judge on Thursday denied Amgen Inc's bid to block the sale of Novartis AG's recently approved "biosimilar" form of ...
 Reuters1 week ago The Swiss Stock Market Pulled Back On Profit Taking  RTTNews.com1 week ago

BRIEF-Novartis says it, Amgen want expedited appellate review of Neupogen decision

(Reuters) - Novartis AG : * Says it, Amgen both agreed to seek expedited review by U.S. appeals court of U.S. district court
 Reuters1 week ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
Related Queries - novartis ag
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
 
More     Less